General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs) : A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Jessop, Helen (Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield, Regne Unit))
Farge-Bancel, Dominique (McGill University)
Saccardi, Riccardo (Careggi University Hospital (Florència, Itàlia))
Alexander, Tobias (Charité-Universitätsmedizin Berlin)
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Sharrack, Basil (University of Sheffield)
Greco, Raffaella (IRCCS San Raffaele Scientific Institute (Milà, Itàlia))
Wulffraat, Nico (Wilhelmina Kinderziekenhuis)
Moore, John (St Vincent's Hospital (Sydney))
Kazmi, Majid (King's College Hospital NHS Foundation Trust)
Badoglio, Manuela (EBMT Paris study office)
Adams, Geert (EBMT Executive Office)
Verhoeven, Bregje (EBMT Executive Office)
Murray, John (Christie Hospital NHS Foundation Trust)
Snowden, John A (Sheffield Teaching Hospitals NHS Foundation Trust (Sheffield, Regne Unit))
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	Over the last 20 years, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with severe autoimmune and inflammatory diseases whose response to standard treatment options has been limited, resulting in a poor long-term prognosis in terms of survival or disability. The vast majority of patients have received autologous HSCT where an increasing evidence-base supports its use in a wide range of autoimmune diseases, particularly relapsing remitting MS, systemic sclerosis and Crohn's disease. Compared with standard treatments for autoimmune diseases, HSCT is associated with greater short-term risks, including a risk of treatment-related mortality and long-term complications. There is a need for a careful appraisal of potential benefits and risks by disease and transplant specialists working closely together with patients and carers to determine individual suitability for HSCT. HSCT should be conducted in accredited transplant centres with robust arrangements for long-term follow-up with both disease and transplant specialists. The aim of this open-access position statement is to provide plainly worded guidance for patients and non-specialist clinicians considering HSCT for an autoimmune disease, especially when treatment abroad is being considered. Recent technical publications in the field have been referenced to support the statement and provide more detail for clinicians advising patients.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Stem cells ; Autoimmune diseases
Publicado en:	Bone marrow transplantation, Vol. 54 Núm. 7 (january 2019) , p. 933-942, ISSN 1476-5365

DOI: 10.1038/s41409-019-0430-7
PMID: 30705338

10 p, 1.3 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Instituto de Investigación contra la Leucemia Josep Carreras
Artículos > Artículos de investigación
Artículos > Artículos publicados